Noxopharm Begins SOF-SKN Manufacturing for Clinical Trials
Key points
- Manufacturing process has started
- Expected to take several weeks
- Low supply chain risks
Full summary
Noxopharm Limited, a clinical-stage biotech company, has announced the commencement of SOF-SKN manufacturing in preparation for a planned clinical trial later this year. The manufacturing process, which is expected to take several weeks, includes quality control checks and utilizes a controlled environment. This efficiency is supported by a favorable active ingredient stability profile, ensuring low supply chain risks. The company plans to use the manufactured product for preclinical investigations and further characterization of SOF-SKN, which is initially being developed for cutaneous lupus erythematosus (CLE) and may expand to other autoimmune-related skin diseases.
Summary generated by a large language model. Please interpret with care.